Ulzerationen unter Therapie mit Hydroxycarbamid

TumorDiagnostik & Therapie 2020; 41(04): 261-262
DOI: 10.1055/a-1139-7745

Thieme Onkologie aktuell

Anna Lena Recke

Klinik für Dermatologie, Allergologie und Venerologie, UKSH Schleswig-Holstein, Campus Lübeck

,

K. Neumann

Klinik für Dermatologie, Allergologie und Venerologie, UKSH Schleswig-Holstein, Campus Lübeck

Literatur
1 Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361 (19) 1872-1885
2 Fram RJ, Kufe DW. Inhibition of DNA excision repair and the repair of x-ray induced DNA damage by cytosine arabinoside and hydroxyurea. Pharmacol Ther 1985; 31 (03) 165-176
3 Boneberger S, Rupec RA, Ruzicka T. Ulcers following therapy with hydroxyurea. Three case reports and review of the literature. Hautarzt 2010; 61 (07) 598-602
4 Soutou B, Aractingi S. Myeloproliferative disorder therapy: assessment and management of adverse events – a dermatologist’s perspective. Hematol Oncol 2009; 27 (Suppl. 01) 11-13
5 Hwang SW, Hong SK, Kim SH. et al. A Hydroxyurea-induced Leg Ulcer. Ann Dermatol 2009; 21 (01) 39-41
6 Knupfer J, Stücker M, Reich-Schupke S. Differenzialdiagnosen von Ulzerationen an Bein und Fuß. Aktuelle Dermatologie 2018; 04: 164-179